Teva Pharmaceutical Industries Limited Seeks To Outbid Rival Endo Health Solutions Inc. With $114 Million NuPathe Inc. Offer

Published: Jan 08, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Teva Pharmaceutical Industries Ltd. (TEVA) offered at least $114 million to acquire U.S. migraine treatment maker NuPathe Inc. (PATH:US), seeking to outbid a previous offer from Endo Health Solutions Inc. (ENDP:US) Teva offered to pay $3.65 a share, plus as much as $3.15 a share if sales goals are achieved related to the migraine drug Zecuity, NuPathe said today in a corporate filing (PATH:US). Endo’s offer, announced Dec. 16, was for $105 million in cash plus as much as $3.15 per share in milestone payments.

Help employers find you! Check out all the jobs and post your resume.

Back to news